灿菲特生物制药是一家临床晚期药物开发公司,其平台技术旨在满足数十亿美元的癌症、炎症性...查看全文
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001013762-24-001791 Act: 34 Size: 22 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-060625 Act: 34 Size: 24 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-058931 Act: 34 Size: 10 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-057535 Act: 34 Size: 42 KB 网页链接
$Can-fite Biopharma(CANF)$ 424B7 Prospectus [Rule 424(b)(7)] Accession Number: 0001213900-24-057194 Act: 33 Size: 42 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-056848 Act: 34 Size: 25 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-056177 Act: 34 Size: 9 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-054980 Act: 34 Size: 22 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-050960 Act: 34 Size: 26 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K/A [Amend] Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-050777 Act: 34 Size: 1 MB 网页链接